Pharmosa Biopharm Balance Sheet Health
Financial Health criteria checks 6/6
Pharmosa Biopharm has a total shareholder equity of NT$1.9B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$2.1B and NT$175.7M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$1.61b |
| Equity | NT$1.90b |
| Total liabilities | NT$175.67m |
| Total assets | NT$2.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6875's short term assets (NT$1.7B) exceed its short term liabilities (NT$66.4M).
Long Term Liabilities: 6875's short term assets (NT$1.7B) exceed its long term liabilities (NT$109.2M).
Debt to Equity History and Analysis
Debt Level: 6875 is debt free.
Reducing Debt: 6875 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6875 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6875 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8% each year